Примери за използване на Carcinogenicity study на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
A long-term carcinogenicity study in mice did not show any carcinogenic potential.
The relevance of the findings from the rat carcinogenicity study for humans is not known.
A long term carcinogenicity study in mice did not show any carcinogenic potential.
In a carcinogenicity study in rats, leflunomide did not show carcinogenic potential.
Nitisinone did not show carcinogenic potential in a 26-week carcinogenicity study in transgenic mice(TgrasH2).
In a carcinogenicity study in rats, leflunomide did not show carcinogenic potential.
Vandetanib has shown no carcinogenic potential effect in a 6 month carcinogenicity study in rasH2 transgenic mice.
In a 6-month carcinogenicity study in transgenic mice, there was no tumorigenic response.
In rats, decreased cellularity of the bone marrow andthymic atrophy were observed only in the carcinogenicity study.
In a 104-week rat carcinogenicity study, no treatment-related tumours were noted in male rats.
The latter finding was not observed in pigmented rats, norin a 2-year albino mouse carcinogenicity study or in any other species investigated.
A two-year mouse carcinogenicity study produced no evidence of carcinogenicity by capecitabine.
Ruxolitinib has been evaluated in safety pharmacology, repeated dose toxicity, genotoxicity andreproductive toxicity studies and in a carcinogenicity study.
A carcinogenicity study with homologous erythropoietin in mice did not reveal any signs of proliferative or tumourigenic potential.
Gastrointestinal neoplasia including hepatobiliary tract In the rat carcinogenicity study, benign tumours were found in the small bowel and the extrahepatic bile ducts.
In a 24-month carcinogenicity study in the rat, abiraterone acetate increased the incidence of interstitial cell neoplasms in the testes.
And 5% of rats in the mid- and high- dose groups, respectively, of the 24-month carcinogenicity study were shown to have renal epithelial tumours(adenomas or carcinomas).
A 6-month carcinogenicity study in Tg. rasH2 transgenic mice and the rat 2-year data showed no signs of carcinogenic potential.
Macitentan induced minimal to slight mucosal hyperplasia andinflammatory infiltration in the submucosa of the nasal cavity in the mouse carcinogenicity study at all doses.
Evaluation of brain slides from the carcinogenicity study in rats revealed brain lesions in animals administered high doses of fentanyl citrate.
The 2009 Addendum(6) to the EU RAR, prepared for the purpose of the transitional measures under Regulation(EC) No 1907/2006, concluded that no furthermeasures at Union level were required, as the results from the two-year carcinogenicity study with inhalation exposure of rats to metallic nickel did not point towards a revision of the existing carcinogenicity classification.
In a carcinogenicity study of haloperidol, dose-dependent increases in pituitary gland adenomas and mammary gland carcinomas were seen in female mice.
It is concluded that as the increase in incidence of tumours in the first transplacental carcinogenicity study represents a hypothetical risk, this should be balanced against the proven therapeutic benefit.
In a 2-year carcinogenicity study in female mice, ospemifene caused treatment related increases in neoplastic findings in the adrenal gland and ovary.
The main findings found in repeat-dose toxicity studies(rat, dog),in a 2-year rat carcinogenicity study, and in toxicity to reproduction studies(rat, rabbit) were limited to injection site reactions for which no NOAEL could be determined.
A carcinogenicity study(daily subcutaneous injections of fentanyl hydrochloride for two years in Sprague Dawley rats) did not induce any findings indicative of oncogenic potential.
In a two-year rat carcinogenicity study, non-neoplastic and neoplastic findings were observed and related or attributed to an exaggerated pharmacological effect.
In a 2-year carcinogenicity study in rats, a clear increase in mostly benign thymic tumours was recorded at all ospemifene dose levels.
In a 2-year dietary carcinogenicity study, benign and malignant Schwannomas have been observed in rats treated with amifampridine(see section 5.3).